149 related articles for article (PubMed ID: 24048635)
41. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
42. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
Andic N; Gunduz E; Akay OM; Şahin D; Teke HÜ
Platelets; 2014; 25(1):69-70. PubMed ID: 23320868
[TBL] [Abstract][Full Text] [Related]
43. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
44. [Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery].
Shomura S; Katayama Y; Kusagawa H; Komada T
Kyobu Geka; 2014 Mar; 67(3):203-6. PubMed ID: 24743530
[TBL] [Abstract][Full Text] [Related]
45. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
46. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
Paul S; Jain N; Ferrajoli A; O'Brien S; Burger J; Keating M; Wierda W
Br J Haematol; 2019 May; 185(3):606-608. PubMed ID: 30406944
[No Abstract] [Full Text] [Related]
47. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
48. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Fattizzo B; Pasquale R; Carpenedo M; Cantoni S; Auteri G; Gramegna D; D'Adda M; Napolitano M; Consonni D; Ruggeri M; Siragusa S; Rossi G; Vianelli N; Barcellini W
Haematologica; 2019 Oct; 104(10):e470-e473. PubMed ID: 30846501
[No Abstract] [Full Text] [Related]
50. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
Gibiansky E; Zhang J; Williams D; Wang Z; Ouellet D
J Clin Pharmacol; 2011 Jun; 51(6):842-56. PubMed ID: 20663993
[TBL] [Abstract][Full Text] [Related]
51. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
52. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
53. [New therapeutic possibilities in chronic ITP in adults].
Jönsson S; Olsson B; Wadenvik H
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1476-9. PubMed ID: 19579436
[No Abstract] [Full Text] [Related]
54. A simple HPLC assay for determining eltrombopag concentration in human serum.
Yanagimachi N; Obara N; Sakata-Yanagimoto M; Chiba S; Doki K; Homma M
Biomed Chromatogr; 2021 May; 35(5):e5049. PubMed ID: 33314287
[TBL] [Abstract][Full Text] [Related]
55. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.
Aslanis V; Zhang J; Lomeli B; Grosch K; Ouatas T
Cancer Chemother Pharmacol; 2018 Nov; 82(5):847-855. PubMed ID: 30171280
[TBL] [Abstract][Full Text] [Related]
56. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau B;
Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
[No Abstract] [Full Text] [Related]
57. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
58. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
59. Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial.
Bowen CJ; Lobb KM; Park JW; Sanderson B; Ferguson J
Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):243-9. PubMed ID: 20831698
[TBL] [Abstract][Full Text] [Related]
60. Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately.
Kanda M; Atsumi T
Lupus; 2018 Oct; 27(11):1876-1877. PubMed ID: 29958500
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
